Free Trial

NeoGenomics (NEO) News Today

NeoGenomics logo
$7.84 +0.28 (+3.70%)
Closing price 06/10/2025 04:00 PM Eastern
Extended Trading
$7.72 -0.13 (-1.59%)
As of 06/10/2025 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NEO Latest News

NeoGenomics, Inc. stock logo
NeoGenomics, Inc. (NASDAQ:NEO) Short Interest Up 32.2% in May
NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) was the recipient of a large increase in short interest in the month of May. As of May 15th, there was short interest totalling 6,280,000 shares, an increase of 32.2% from the April 30th total of 4,750,000 shares. Approximately 5.0% of the shares of the stock are sold short. Based on an average trading volume of 2,070,000 shares, the short-interest ratio is currently 3.0 days.
NeoGenomics, Inc. stock logo
NeoGenomics, Inc. (NASDAQ:NEO) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 7.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 646,111
NeoGenomics, Inc. stock logo
Nuveen Asset Management LLC Sells 98,179 Shares of NeoGenomics, Inc. (NASDAQ:NEO)
Nuveen Asset Management LLC lessened its stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 22.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 345,667 shares of the medical resear
NeoGenomics, Inc. stock logo
NeoGenomics, Inc. (NASDAQ:NEO) Director Michael Aaron Kelly Purchases 5,000 Shares
NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) Director Michael Aaron Kelly acquired 5,000 shares of the firm's stock in a transaction dated Tuesday, May 27th. The stock was bought at an average price of $7.60 per share, with a total value of $38,000.00. Following the purchase, the director now directly owns 5,000 shares in the company, valued at approximately $38,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
NeoGenomics, Inc. stock logo
BNP Paribas Financial Markets Sells 35,979 Shares of NeoGenomics, Inc. (NASDAQ:NEO)
BNP Paribas Financial Markets trimmed its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 49.3% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 36,984 shares of the medical research company's stock after selling 35,979 shares durin
NeoGenomics, Inc. stock logo
NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Rating of "Hold" from Analysts
NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) has been given an average rating of "Hold" by the eleven ratings firms that are presently covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on th
NeoGenomics, Inc. stock logo
Graham Capital Management L.P. Acquires 51,626 Shares of NeoGenomics, Inc. (NASDAQ:NEO)
Graham Capital Management L.P. raised its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 467.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 62,669 shares of the medical research company's stock after buyi
NeoGenomics, Inc. stock logo
Janus Henderson Group PLC Has $101.60 Million Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
Janus Henderson Group PLC lessened its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 6.6% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 6,165,063 shares of the medical research company's stock after selling 438,117 shares during the
NeoGenomics, Inc. stock logo
Schonfeld Strategic Advisors LLC Sells 54,330 Shares of NeoGenomics, Inc. (NASDAQ:NEO)
Schonfeld Strategic Advisors LLC lowered its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 76.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 16,280 shares of the medical research com
NeoGenomics, Inc. stock logo
NeoGenomics (NASDAQ:NEO) Upgraded to Hold at StockNews.com
StockNews.com upgraded shares of NeoGenomics from a "sell" rating to a "hold" rating in a report on Tuesday.
NeoGenomics, Inc. stock logo
Northern Trust Corp Boosts Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)
Northern Trust Corp grew its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 7.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,621,809 shares of the medical research company's stock
NeoGenomics, Inc. stock logo
NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Price T Rowe Associates Inc. MD
Price T Rowe Associates Inc. MD lowered its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 78.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 91,574 shares of the medical research company's stock aft
NeoGenomics, Inc. stock logo
NeoGenomics, Inc. (NASDAQ:NEO) Position Lowered by Fred Alger Management LLC
Fred Alger Management LLC reduced its position in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 3.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,712,959 shares of the medical research company's sto
NeoGenomics, Inc. stock logo
Voya Investment Management LLC Has $1.02 Million Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
Voya Investment Management LLC decreased its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 98.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 61,688 shares of the
NeoGenomics, Inc. stock logo
Tudor Investment Corp ET AL Cuts Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
Tudor Investment Corp ET AL lessened its position in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 59.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 87,353 shares of the medical research c
NeoGenomics, Inc. stock logo
First Trust Advisors LP Raises Holdings in NeoGenomics, Inc. (NASDAQ:NEO)
First Trust Advisors LP lifted its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 316.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 132,180 shares of the medical research company's stock after purch
NeoGenomics, Inc. stock logo
Raymond James Financial Inc. Takes $839,000 Position in NeoGenomics, Inc. (NASDAQ:NEO)
Raymond James Financial Inc. purchased a new position in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 50,906 shares of the medical resear
NeoGenomics, Inc. stock logo
NeoGenomics (NASDAQ:NEO) Trading 5.3% Higher - Here's What Happened
NeoGenomics (NASDAQ:NEO) Shares Up 5.3% - Time to Buy?
NeoGenomics, Inc. stock logo
NeoGenomics, Inc. (NASDAQ:NEO) Shares Sold by Brown Advisory Inc.
Brown Advisory Inc. cut its position in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 10.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,156,061 shares of the medical research company's stock after sellin
Momentum stocks
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays (NEO)
These three stocks may fly under the radar, but their recent price increases could appeal to investors seeking a momentum play.
NeoGenomics, Inc. stock logo
Bellevue Group AG Sells 556,816 Shares of NeoGenomics, Inc. (NASDAQ:NEO)
Bellevue Group AG lowered its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 34.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,055,796 shares of the medical research company's sto
NeoGenomics, Inc. stock logo
Dimensional Fund Advisors LP Buys 78,211 Shares of NeoGenomics, Inc. (NASDAQ:NEO)
Dimensional Fund Advisors LP raised its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 2.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 3,436,858 shares of the medical research company's stock after purchasing an additi
NeoGenomics, Inc. stock logo
NeoGenomics (NASDAQ:NEO) Downgraded by Leerink Partnrs to "Hold"
Leerink Partnrs cut NeoGenomics from a "strong-buy" rating to a "hold" rating in a report on Wednesday.
NeoGenomics, Inc. stock logo
NeoGenomics (NASDAQ:NEO) Rating Lowered to "Market Perform" at Leerink Partners
Leerink Partners lowered NeoGenomics from an "outperform" rating to a "market perform" rating and decreased their price objective for the company from $25.00 to $9.00 in a report on Wednesday.
NeoGenomics, Inc. stock logo
NeoGenomics (NASDAQ:NEO) Hits New 52-Week Low on Analyst Downgrade
NeoGenomics (NASDAQ:NEO) Sets New 52-Week Low on Analyst Downgrade
NeoGenomics, Inc. stock logo
Needham & Company LLC Cuts NeoGenomics (NASDAQ:NEO) Price Target to $8.50
Needham & Company LLC reduced their price objective on shares of NeoGenomics from $18.00 to $8.50 and set a "buy" rating on the stock in a research note on Tuesday.
NeoGenomics, Inc. stock logo
NeoGenomics (NASDAQ:NEO) Issues Quarterly Earnings Results
NeoGenomics (NASDAQ:NEO - Get Free Report) posted its quarterly earnings results on Tuesday. The medical research company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.06). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The business's revenue for the quarter was up 7.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.02) earnings per share.
NeoGenomics, Inc. stock logo
NeoGenomics (NASDAQ:NEO) Shares Gap Down After Earnings Miss
NeoGenomics (NASDAQ:NEO) Shares Gap Down Following Weak Earnings
NeoGenomics, Inc. stock logo
Emerald Mutual Fund Advisers Trust Has $17.59 Million Stake in NeoGenomics, Inc. (NASDAQ:NEO)
Emerald Mutual Fund Advisers Trust lessened its stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 13.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,067,400 shares of the medical research company's stock after se
NeoGenomics, Inc. stock logo
NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Moderate Buy" by Brokerages
NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten analysts that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the c
NeoGenomics, Inc. stock logo
NeoGenomics (NASDAQ:NEO) Shares Down 4.9% - Here's Why
NeoGenomics (NASDAQ:NEO) Shares Down 4.9% - What's Next?
Get NeoGenomics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.

Related Videos

Top 3 Insider Stock Buys in April—Are They Still Good in May?

NEO Media Mentions By Week

NEO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NEO
News Sentiment

0.47

1.00

Average
Medical
News Sentiment

NEO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NEO Articles
This Week

2

5

NEO Articles
Average Week

Get NeoGenomics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:NEO) was last updated on 6/11/2025 by MarketBeat.com Staff
From Our Partners